ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.

NBSE NeuBase Therapeutics Inc

0.3996
-0.0054 (-1.33%)
Última actualización: 12:18:29
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
NeuBase Therapeutics Inc NBSE NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
-0.0054 -1.33% 0.3996 12:18:29
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
0.3766 0.36 0.399799 0.405
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
06/5/202406:30EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
05/4/202415:05GLOBENeuBase Therapeutics Announces Receipt of Notice from Nasdaq
07/3/202415:01EDGAR2Form 8-K - Current report
23/2/202415:01EDGAR2Form 8-K - Current report
26/1/202407:00EDGAR2Form 8-K - Current report
17/1/202405:15EDGAR2Form 8-K - Current report
28/12/202306:00EDGAR2Form 8-K - Current report
28/12/202305:15EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
22/12/202305:15EDGAR2Form 8-K - Current report
27/11/202308:00GLOBEPsychemedics Corporation Appoints Daniella Mehalik as VP -..
09/11/202315:11EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06/11/202316:00EDGAR2Form 8-K - Current report
20/10/202306:30EDGAR2Form 8-K - Current report
18/10/202307:00EDGAR2Form 8-K - Current report
29/9/202315:10EDGAR2Form 8-K - Current report
20/9/202319:42EDGAR2Form 5 - Annual statement of changes in beneficial ownership..
20/9/202316:28EDGAR2Form SC 13D/A - General statement of acquisition of..
18/9/202315:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/9/202315:20EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
18/9/202315:17EDGAR2Form 8-K - Current report
14/9/202305:03EDGAR2Form SC 13D/A - General statement of acquisition of..
11/9/202316:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/9/202306:00GLOBENeuBase Therapeutics Issues Statement Regarding Filing By..
07/9/202316:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/9/202309:00PRNUSSYMETRYX CORPORATION ACQUIRES 20% STOCK IN NEUBASE
31/8/202310:50EDGAR2Form SC 13D - General statement of acquisition of beneficial..
14/8/202315:11EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/8/202305:18EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
11/8/202305:15EDGAR2Form DEF 14A - Other definitive proxy statements
10/8/202316:13EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
04/8/202315:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/8/202306:05EDGAR2Form 8-K - Current report
01/8/202315:45EDGAR2Form PRE 14A - Other preliminary proxy statements
31/7/202315:10EDGAR2Form 8-K - Current report
28/7/202305:03EDGAR2Form S-1 - General form for registration of securities under..
30/6/202315:21EDGAR2Form 8-K - Current report
30/6/202307:42EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
30/6/202307:41EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]

Su Consulta Reciente

Delayed Upgrade Clock